MIMediolanum International Funds Ltd
Institutional investor · Portfolio as of Q1 2024
Top Holdings377 positions
Microsoft Corp. | 974,049 | $410.5M | 6.7% | $412.69 | 0.00% | 1 qtr | First report 0 |
Apple Inc. | 2.3M | $406.4M | 6.6% | $169.63 | 0.00% | 1 qtr | First report 0 |
NVIDIA Corp. | 362,923 | $327.5M | 5.3% | $90.10 | 0.00% | 1 qtr | First report 0 |
Alphabet Inc. | 1.1M | $171M | 2.8% | $149.51 | 0.00% | 1 qtr | First report 0 |
Alphabet Inc. | 840,132 | $127.6M | 2.1% | $150.83 | 0.00% | 1 qtr | First report 0 |
Meta Platforms Inc | 242,961 | $120M | 1.9% | $481.48 | 0.00% | 1 qtr | First report 0 |
UnitedHealth Group Inc. | 225,223 | $111.1M | 1.8% | $467.99 | 0.00% | 1 qtr | First report 0 |
Amazon.com, Inc. | 555,843 | $100M | 1.6% | $180.38 | 0.00% | 1 qtr | First report 0 |
Merck & Co., Inc | 694,125 | $91.5M | 1.5% | $122.06 | 0.00% | 1 qtr | First report 0 |
APPLIED MATLS INC | 419,462 | $87.2M | 1.4% | $202.44 | 0.00% | 1 qtr | First report 0 |
Adobe Inc | 169,642 | $85.6M | 1.4% | $504.60 | 0.00% | 1 qtr | First report 0 |
EXXON MOBIL CORP | 677,025 | $77.8M | 1.3% | $108.71 | 0.00% | 1 qtr | First report 0 |
Accenture PLC | 221,599 | $75.6M | 1.2% | $330.74 | 0.00% | 1 qtr | First report 0 |
SALESFORCE COM INC | 249,103 | $75.1M | 1.2% | $296.44 | 0.00% | 1 qtr | First report 0 |
Broadcom Inc | 56,842 | $75M | 1.2% | $129.45 | 0.00% | 1 qtr | First report 0 |
MasterCard Incorporated | 133,050 | $63.6M | 1.0% | $474.49 | 0.00% | 1 qtr | First report 0 |
Thermo Fisher Scientific Inc | 101,838 | $59M | 1.0% | $576.38 | 0.00% | 1 qtr | First report 0 |
Eli Lilly & Co. | 70,111 | $54.6M | 0.9% | $764.84 | 0.00% | 1 qtr | First report 0 |
NIKE INC | 554,631 | $52.2M | 0.8% | $88.27 | 0.00% | 1 qtr | First report 0 |
BK OF AMERICA CORP | 1.3M | $49.5M | 0.8% | $35.82 | 0.00% | 1 qtr | First report 0 |
Mediolanum International Funds Ltd manages $6.2B across 377 positions as of Q1 2024. Top holdings: MSFT (6.7%), AAPL (6.6%), NVDA (5.3%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2/5.0.
First quarter we have for this fund: 377 positions, nothing earlier to compare. No standout high-conviction moves this quarter. Portfolio: $6.2B across 377 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR